Le Lézard
Classified in: Health, Science and technology, Business
Subjects: VEN, RCN

Canepa Healthcare changes name to Evidity Health Capital


NEW YORK and MIAMI, Dec. 10, 2019 /PRNewswire/ -- Canepa Healthcare, the late-stage venture capital and growth equity firm focusing on medical technology, unveiled its new name today, Evidity Health Capital.

The new brand reflects Evidity's value-focused, evidence-based, business-building approach to investing in the medtech sector. The firm enters 2020 increasing its focus on an industry characterized by sustained growth, many growth stage companies, and an expanding exit universe.

"Through the past five years we have invested in businesses defined by the clinical and health economic value they deliver to patients, physicians, health systems, payers, and employers," said Managing Director Paul Enever. "These are businesses taking the high ground of quality evidence in their respective markets, and that are ready to achieve the next level of performance through disciplined execution."

"As we continue our strategy into 2020, we have decided to adopt a new name that best reflects both the roots and direction of the firm," said Principal Dr. Adam Lessler. "Evidity is derived from three words that capture our investment philosophy - evidence; vidi, meaning 'I saw' in Latin; and quality. This summarizes our intent to invest in companies when and where we see proof of excellence."

The Evidity investment team methodically and collectively evaluates the data supporting a product's and business' value proposition to assess its strength and repeatability. The team focuses on identifying and developing essential bodies of data that enable regulatory approval, coverage and payment, clinician adoption, and hospital purchasing.

"We are the same team with the same focus, and with five years behind us, even better defined," said Managing Director Alejandro Sanchez. "We continue to be proud of our collaborative reputation and rolling up our sleeves to facilitate the level of execution we expect from portfolio companies. Now we are setting the stage both in our name and in our planning for new growth in our platform and in our portfolio."

About Evidity

Evidity is a late-stage venture capital and growth equity firm centered on complementary expertise and a disciplined investment approach. The firm is led by a cohesive team of three investment partners who bring diverse and complementary skillsets yet share a common background, working approach, and values. The firm has a culture and operating model where all partners share responsibility for the success of each investment decision and portfolio company's performance. For more information please visit Evidity.com.

Contact - Christopher Gale, 203-570-4681, [email protected]

SOURCE Evidity Health Capital


These press releases may also interest you

at 00:25
Shanghai Junshi Biosciences Co., Ltd ("Junshi Biosciences," HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced its financial...

28 mar 2024
The report titled "Central Lab Market by Service Type (Anatomic Pathology/Histology, Biomarker Services, Genetic Services), Phase (Phase 1, Phase 2, Phase 3), Therapeutic Area, End-use - Global Forecast 2024-2030" is now available on...

28 mar 2024
The report titled "Personalized Nutrition Market by Measurement Type (Active Measurement, Standard Measurement), Application (Indication-based, Standard Supplements), Distribution Channel, End-Use - Global Forecast 2024-2030" is now available on...

28 mar 2024
The report titled "Carbon Dioxide Incubator Market by Product (Air Jacketed CO2 Incubators, Direct Heat CO2 Incubators, Water Jacketed CO2 Incubators), Capacity (100-200 Litre, Above 200 Litre, Below 100 Litre), Application, End User - Global...

28 mar 2024
The "Global Clinical In Vitro Diagnostic Medical Laboratory Services Market: Strategy & Trends with Volume & Price Forecasts by Chemistry, Hematology, Microbiology, Pathology, Covid-19, and Molecular Dx by Country. Updated with Impact of COVID-19"...

28 mar 2024
The "Molecular Diagnostics at the Point of Care. By Application, Technology, Place, Product and by Country. With Executive Guides and Customization 2023 - 2027 " report has been added to  ResearchAndMarkets.com's offering. Infectious disease Dx is...



News published on and distributed by: